GLTO רווח נקי למניה ב-12 החודשים האחרונים galecto.com
Galecto, Inc. develops galectin inhibitors for the treatment of severe liver and lung pathologies, leveraging large-scale R&D investments. The company's biochemistry aims to stop tissue scarring in cancer and fibrosis. The current change in the rolling annual EPS on GURU.Markets indicates a pipeline revision stage, where -12.09 reflects the metric's baseline until new onco-molecules generate a commercial effect.
%20%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%9E%D7%A0%D7%99%D7%94%20%D7%91%D7%90%D7%A8%D7%91%D7%A2%D7%AA%20%D7%94%D7%A8%D7%91%D7%A2%D7%95%D7%A0%D7%99%D7%9D%20%D7%94%D7%90%D7%97%D7%A8%D7%95%D7%A0%D7%99%D7%9D&width=1200&height=400&colorIndex=0&v=mwa76aez.ocr-7cpmfb4&start=20220704&end=20261110&filename=GURU_Markets_-_GLTO_-_Galecto-Inc._-_Earnings-per-share-for-the-last-four-quarters "Galecto Corp - רווח נקי למניה (EPS TTM) GLTO (תקופה 04.07.2022 - 10.03.2026) | 👁️GURU.Markets👁️")
פילוחים אנליטיים ודוחות נתונים של חברת Galecto Inc (GLTO)
Galecto, Inc. (GLTO) focuses on capturing market share in metabolic pharma through the development of galectin inhibitors. Earnings per share over the trailing twelve months (EPS TTM) measures the final financial result allocated to a single security. This metric smooths out one-time market shocks, demonstrating the actual efficiency of the business. A slowdown in the trend line signals a decline in demand. By analyzing the EPS TTM dynamics of Galecto, Inc. (GLTO), an investor assesses the fundamental stability of the expansion strategy.
